Section 232 tariffs on patented medicines reach every remaining importer today, with rates running from zero to 100 percent depending on pricing deals, onshoring commitments and country of origin
WASHINGTON, Sept. 29, 2026. The second and final phase of the United States’ Section 232 pharmaceutical tariff regime takes effect today, extending duties on patented medicines and active pharmaceutical ingredients to every importer not already covered by the accelerated July 31 start date.
The action completes the implementation schedule set out in the presidential proclamation signed April 2, 2026, titled “Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States.” That proclamation applied tariffs to 17 large manufacturers listed in Annex III at the 120-day mark. Today, at 180 days, the regime becomes universal across covered products.
For importers, today is less a policy announcement than a compliance deadline that has been visible for six months and that many have spent those six months trying to engineer around. The engineering has been substantial, and the results are uneven.
A rate structure built to be escaped
The headline rate is 100 percent ad valorem on patented pharmaceuticals and active pharmaceutical ingredients. Almost no one will pay it.
The proclamation establishes a tiered structure in which the default rate functions as a penalty for non-participation rather than as a revenue measure. The tiers, as they stand today, are:
A zero rate applies to companies that have both an approved onshoring plan and a most favored nation pricing agreement with the Department of Health and Human Services. That rate runs through Jan. 20, 2029.
A 10 percent rate applies to United Kingdom origin product, reflecting the bilateral framework agreed with London. Reporting on the UK position varies, with some analyses describing the effective UK rate as zero from July 31, 2026, contingent on major UK companies maintaining compliance agreements with Commerce and HHS through Jan. 19, 2029.
A 15 percent rate applies to product originating in the European Union, Japan, South Korea, Switzerland and Liechtenstein. This rate is all-inclusive, replacing rather than stacking on the underlying most favored nation duty.
A 20 percent rate applies to companies holding an approved onshoring plan but no MFN pricing agreement. That rate is scheduled to rise to 100 percent on April 2, 2030, giving companies a four-year runway to complete the manufacturing commitments the plan describes.
The 100 percent default applies to everyone else, indefinitely.
Where more than one rate could apply under the proclamation, the lowest governs. The Section 232 duty is assessed alongside the applicable Column 1 rate from the Harmonized Tariff Schedule, and where the Column 1 rate exceeds the proclamation rate, only Column 1 applies. Antidumping and countervailing duty orders continue to apply cumulatively on top.
What is covered and what is not
Annex I of the proclamation lists approximately 120 ten-digit HTSUS codes carrying active tariff rates. Coverage spans Chapter 29 of the tariff schedule, organic chemicals including drug-specific compounds such as antihistamines, antidepressants and cardiovascular agents, and Chapter 30, finished medicaments, biologics, antisera, monoclonal antibodies and vaccines.
The operative definition is patent status. Covered articles are pharmaceutical products subject to a valid, unexpired United States patent as listed in the Food and Drug Administration’s Orange Book or Purple Book, together with the associated APIs and key starting materials.
The exclusions are extensive and, for the American healthcare system, decisive.
Generic pharmaceuticals and biosimilars are excluded. Because generics account for roughly nine in ten prescriptions dispensed in the United States, this single carve-out removes the overwhelming majority of prescription volume from the tariff’s reach. The exclusion is expressly conditional. The proclamation requires the Secretary of Commerce to assess within one year whether to extend the tariffs to generic products, which means the industry has until roughly April 2027 before the question reopens.
Orphan drugs are excluded across all approved indications designated under the Orphan Drug Act. Also excluded are nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody drug conjugates, medical countermeasures for chemical, biological, radiological and nuclear threats, animal health products, developmental prototypes and products of United States origin.
Annex IV contains roughly 400 additional HTSUS codes set at a zero rate, including vitamin classifications, broad-spectrum antibiotics such as ampicillin, streptomycins and tetracyclines, and cortisone-family steroids.
Products from jurisdictions with trade and security framework agreements addressing urgent health needs receive separate treatment.
The national security findings
Section 232 requires a finding that imports threaten to impair national security, and the April proclamation rests on supply chain concentration rather than on any conventional defense rationale.
The proclamation cites FDA figures indicating that approximately 53 percent of patented pharmaceutical products distributed domestically are manufactured outside the United States, and that only about 15 percent of patented active pharmaceutical ingredients by volume are produced domestically. It characterizes the resulting dependency as a vulnerability during geopolitical disruption, and it identifies foreign government intervention in pharmaceutical pricing as a factor undermining American competitiveness.
That second finding is the connective tissue between the tariff and the drug pricing agenda. By conditioning the zero rate on an MFN pricing agreement, the administration has fused a trade instrument to a domestic healthcare pricing objective. A manufacturer seeking tariff relief must commit to offering the United States pricing no worse than the most favorable price it offers any other developed country.
The legal authority is Section 232 of the Trade Expansion Act of 1962, together with Section 604 of the Trade Act of 1974. That matters more than usual. The Supreme Court’s February 2026 decision invalidated tariffs imposed under emergency economic powers, and analysts have been careful to note that the pharmaceutical tariffs rest on a different statutory foundation, one with a long history of judicial deference to executive national security findings.
How the industry responded
The pharmaceutical industry’s response has been to negotiate rather than litigate, and the negotiation has moved quickly.
By Aug. 31, 2026, 26 manufacturers had entered MFN pricing agreements. A White House announcement that month unveiled nine additional deals with midsized drugmakers, bringing the combined branded market share covered by such agreements to approximately 89 percent. Those nine companies committed nearly $20 billion to United States manufacturing, and four pledged ingredient supply to a Strategic API Reserve.
Thirteen companies are identified in Annex II as having executed agreements qualifying for the zero rate. Four additional major manufacturers, reported as Pfizer, Regeneron, GlaxoSmithKline and its ViiV joint venture, and Johnson and Johnson, were described as being in active negotiation.
Cumulative announced investment commitments tied to pharmaceutical onshoring have been reported at roughly $400 billion, a figure that spans multi-year capital programs of varying specificity and that should be read as an aggregate of corporate announcements rather than as verified capital deployment.
The strategic logic behind the industry’s accommodation is straightforward. A 100 percent duty on a patented medicine is not a cost to be absorbed or passed through in a market where payers negotiate hard and formulary exclusion is a live threat. It is a commercial impossibility for most products. Faced with that, signing a pricing agreement and committing capital to American plants became the rational path even for companies that objected to the policy.
Economic impact: concentrated, not broad
The tariff’s macroeconomic footprint is narrower than the 100 percent headline suggests, for three reasons.
First, the generic exclusion removes the vast majority of prescription volume. Patients filling routine prescriptions for cardiovascular, metabolic or psychiatric medications are overwhelmingly receiving generic product that carries no Section 232 duty.
Second, the tier structure means that the large majority of covered branded volume, roughly 89 percent by branded market share according to the August figures, enters at the zero rate under MFN pricing agreements.
Third, the country tiers cap exposure for the largest sources of American pharmaceutical imports. Ireland, Germany, Switzerland, Belgium, Japan and South Korea collectively account for a dominant share of branded pharmaceutical and API imports, and all sit in the 15 percent band or below.
The residual exposure is concentrated in a few places: patented products from origins outside the named country tiers, manufactured by companies without pricing agreements or approved onshoring plans. That is a meaningful category for specific specialty and niche products, and an immaterial one in aggregate.
The broader tariff context is useful for scale. The American average effective tariff rate stood at 6.7 percent in July 2026, against 2.3 percent in January 2025. Steel and aluminum carried the highest sectoral rate at 40.5 percent, automotive vehicles 13 percent. Pharmaceutical duty collections will sit well below those categories precisely because the regime was designed to induce behavior rather than to collect revenue.
The cost that does not show up in customs receipts is the pricing commitment. Manufacturers that signed MFN agreements accepted reference pricing against other developed markets in exchange for tariff relief. The revenue consequence of that trade, spread across the branded portfolio over the agreement period to January 2029, is likely to exceed any plausible duty liability the companies avoided.
How the regime was built
The pharmaceutical action did not arrive without warning. The Department of Commerce opened a Section 232 investigation into pharmaceuticals and pharmaceutical ingredients in the spring of 2025, part of a broad expansion of sectoral national security investigations that has since extended to semiconductors, copper, medical goods, machine tools and industrial robotics.
The investigation ran alongside a parallel domestic effort on drug pricing built around the most favored nation concept, the proposition that the United States should not pay more for a medicine than other wealthy countries pay for the same product. Those two workstreams, one a trade instrument and one a health policy objective, converged in the April 2 proclamation.
The convergence is the policy’s defining feature and its principal vulnerability. Section 232 requires the President to find that imports threaten to impair national security and to adjust imports accordingly. The pharmaceutical proclamation makes that finding on supply chain concentration grounds, citing the 53 percent foreign manufacturing share for patented products distributed domestically and the 15 percent domestic share of patented API production by volume. It then makes tariff relief contingent not only on relocating production, which addresses the stated finding directly, but also on accepting reference pricing, which does not.
Trade lawyers have noted the tension without predicting that it will be litigated successfully. Section 232 has historically drawn substantial judicial deference, and the industry’s decision to negotiate rather than sue has removed the most likely plaintiffs from the field.
The pricing bargain in detail
An MFN pricing agreement commits a manufacturer to offer the United States pricing no worse than the most favorable price it offers to any other developed country. The agreements are administered through the Department of Health and Human Services and, on the tariff side, run to Jan. 20, 2029.
The sequence of adoption tells the story of how the leverage worked. Twenty-six manufacturers had signed by Aug. 31, 2026. The August White House announcement added nine midsized drugmakers, a cohort that had less capacity than the largest firms to absorb duty or to restructure supply chains quickly, and whose accession pushed covered branded market share to approximately 89 percent. Those nine committed nearly $20 billion in domestic manufacturing investment, and four agreed to supply the Strategic API Reserve, a stockpiling mechanism aimed at the ingredient concentration the proclamation identified.
The onshoring plans are the second lever. A company with an approved plan but no pricing agreement pays 20 percent rather than 100. The plan must be approved by the Secretary of Commerce against criteria published in the Federal Register, and the 20 percent rate converts to 100 percent on April 2, 2030, which sets a hard four-year deadline for the promised capacity to exist. The proclamation also requires a 90-day review of negotiation progress, giving the administration a recurring checkpoint.
Reported aggregate investment commitments across the sector total roughly $400 billion. That figure warrants care. It aggregates multi-year corporate capital announcements of varying specificity, some of which predate the proclamation and some of which would likely have proceeded regardless. It is a directional indicator of intent, not an audited capital account.
Who else is affected
Hospitals and health systems face exposure concentrated in the specialty and infused product categories that sit outside the generic exclusion. Systems with significant 340B volume or heavy oncology and immunology utilization should map their branded purchasing against the manufacturer agreement list, because a product from a non-signatory manufacturer in a non-tiered origin is the scenario where a 100 percent duty could reach a hospital pharmacy budget.
Contract manufacturers and API suppliers sit in the most complicated position. A contract development and manufacturing organization producing both patented and generic product from the same facility must be able to document, shipment by shipment, which output serves which end use. The proclamation’s authorization for CBP to demand any necessary information makes that documentation burden real rather than theoretical.
European and Asian exporters received the most favorable treatment available short of a pricing agreement. The 15 percent all-inclusive rate for the European Union, Japan, South Korea, Switzerland and Liechtenstein covers the origins that supply the bulk of American branded pharmaceutical imports, and its all-inclusive character means it replaces rather than compounds the underlying duty. Ireland, Germany, Belgium and Switzerland in particular host the manufacturing base for a large share of the patented products sold in the United States.
Generic manufacturers are exempt today and on notice for tomorrow. The one-year review obligation means Commerce must decide by roughly April 2027 whether to extend coverage. Given that generics account for the overwhelming majority of American prescriptions and operate at margins measured in single-digit percentages, an extension would be a materially different policy from the one taking effect today.
Patients are, for now, largely insulated. The combination of the generic exclusion, the 89 percent branded coverage at the zero rate, and the country tiers means that the tariff’s direct pass-through to retail and specialty pharmacy prices should be limited in the near term. The indirect effect of the pricing agreements runs the other way, toward lower list prices on covered branded products, though the extent to which reference pricing reaches patient out-of-pocket costs depends on benefit design rather than on trade policy.
Compliance obligations that begin today
For importers of record, today changes the operational picture in several specific ways.
Classification at the ten-digit level is now duty-determinative. With approximately 120 codes in Annex I at active rates and approximately 400 in Annex IV at zero, the distinction between a covered and an uncovered line is the distinction between a 100 percent duty and none. Misclassification carries penalty exposure under 19 U.S.C. 1592 in addition to the duty itself. Importers should have completed a classification review against both annexes; those who have not should treat it as the immediate priority.
Dual-use APIs require documentation and segregation. Many active ingredients serve both patented and generic products. The proclamation authorizes Customs and Border Protection to require any information necessary to administer the applicable headings. Importers relying on the generic exclusion for a dual-use API should segregate shipments by end use and maintain documentation supporting the claim. An undocumented generic claim on a dual-use ingredient is an audit finding waiting to happen.
Foreign trade zone status must be set correctly at admission. Pharmaceutical products entering an FTZ must be admitted under privileged foreign status pursuant to 19 CFR 146.41, which fixes duty exposure at the classification and rate in effect on the date of admission. Companies with product already in zones should confirm the status under which it was admitted.
Agreement status must be documented and monitored. Companies claiming the zero or 20 percent rates must maintain records supporting their MFN pricing agreement or onshoring plan status. The proclamation establishes external audit requirements and monitoring mechanisms, and provides that non-compliance triggers tariff increases applied both retroactively and prospectively. A lapse is not merely a future rate change; it reopens closed entries.
Duty drawback is available on re-export. Pharmaceutical products re-exported after importation qualify for drawback. Companies with regional distribution hubs in the United States serving Canadian, Latin American or other markets should quantify the drawback opportunity, which for high-value patented product can be substantial.
Entry summaries need review for stacking. The interaction between the Section 232 rate, the Column 1 rate and any applicable AD/CVD orders produces a combined liability that brokers may compute incorrectly in the first weeks of the new phase. Importers should audit a sample of entries filed in early October against their own calculations.
Implications beyond the pharmaceutical supply chain
Today’s deadline carries signals for sectors that have nothing to do with medicine.
The most important is the template. The pharmaceutical proclamation demonstrates a model in which a Section 232 tariff is set at a prohibitive default rate and then waived in exchange for behavior the administration wants: domestic capital investment, and in this case pricing concessions on a separate policy axis. Section 232 investigations are open or recently concluded across medical goods, machine tools, industrial robotics, semiconductors, copper and derivative products. Companies in those sectors should assume the pharmaceutical structure is available to be reused.
The second signal concerns the durability of the instrument. With emergency-powers tariffs invalidated in February and refund litigation continuing, Section 232 has become the administration’s most reliable tariff authority. Its sectoral, origin-neutral character means that relief negotiated bilaterally, including under the 30-for-30 framework announced with China this week, does not reach it.
The third is the conditional nature of the generic exclusion. The one-year review requirement means the single largest carve-out in the regime has a scheduled reopening date. Generic manufacturers, distributors, pharmacy benefit managers and hospital systems have roughly six months to prepare positions for that proceeding. Given that generics supply the overwhelming majority of American prescriptions and operate on margins that cannot absorb meaningful duty, the review will be among the more consequential trade proceedings of 2027.
For importers generally, the lesson of the past six months is that the six-month runway between proclamation and universal effective date was the negotiating window, and the companies that used it are entering today at zero while the companies that waited are entering at 100.